

Pulmonary Embolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/PFC1F1E9CCD7EN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: PFC1F1E9CCD7EN

Abstracts

The 7 major pulmonary embolism markets reached a value of US\$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.58% during 2024-2034.

The pulmonary embolism market has been comprehensively analyzed in IMARC's new report titled "Pulmonary Embolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pulmonary embolism (PE) is a condition that occurs when a blood clot, usually originating in the legs or deep veins of the body, travels to the lungs and blocks one or more of the lung's blood vessels. This can cause damage to the lungs and reduce the amount of oxygen reaching the body's vital organs. PE can be life-threatening if not treated promptly. Symptoms of PE can range from mild to severe, depending on the size and location of the clot. Some of the common symptoms of PE are shortness of breath, chest pain, and coughing up blood. Various other indications may include light-headedness, rapid heartbeat, and leg swelling. Diagnosis of PE typically involves a combination of tests, including a chest X-ray, CT scan, and blood tests. A D-dimer test is also done to see if there is an elevated level of a protein fragment that is produced when a clot is breaking down. Pulmonary embolism treatment typically involves using blood thinners, such as heparin or warfarin, to dissolve the blood clot and prevent further clots from forming. In some cases, catheter-directed thrombolysis or mechanical thrombectomy may be used to remove the clot.

The expanding obese population and the rising incidences of certain inflammatory conditions, such as lupus and rheumatoid arthritis, are primarily driving the global pulmonary embolism market. In addition to this, the growing prevalence of several

associated risk factors, such as addiction to smoking, patients undergoing chemotherapy, the inflating usage of supplemental estrogen and hormone replacement therapy, etc., is also bolstering the market growth. Moreover, the widespread adoption of thrombolytic treatment, which utilizes medications to break up existing blood clots, for treating patients with severe lung damage is further creating a positive outlook for the market. Besides this, the emerging popularity of vena cava filters among patients who are unable to take anticoagulant medicines is also augmenting the global market. In this treatment, a small device is inserted into the vena cava (a large vein in the abdomen) to restrict blood clots from traveling to the lungs. Additionally, the elevating utilization of compression stockings for increasing blood flow in the legs in order to prevent the formation of blood clots is acting as another significant growth-inducing factor. Furthermore, the escalating popularity of direct oral anticoagulants (DOACs), which prevent blood clots while having fewer drug-drug interactions and do not require regular monitoring, is also expected to drive the global pulmonary embolism market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the pulmonary embolism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pulmonary embolism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pulmonary embolism market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pulmonary embolism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pulmonary embolism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pulmonary embolism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the pulmonary embolism market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the pulmonary embolism market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the pulmonary embolism market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pulmonary embolism across the seven major markets?

What is the number of prevalent cases (2018-2034) of pulmonary embolism by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of pulmonary embolism by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of pulmonary embolism by type across the seven major markets?

How many patients are diagnosed (2018-2034) with pulmonary embolism across the seven major markets?

What is the size of the pulmonary embolism patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of pulmonary embolism?

What will be the growth rate of patients across the seven major markets?

Pulmonary Embolism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pulmonary embolism drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pulmonary embolism market?

What are the key regulatory events related to the pulmonary embolism market?

What is the structure of clinical trial landscape by status related to the pulmonary embolism market?

What is the structure of clinical trial landscape by phase related to the pulmonary embolism market?

What is the structure of clinical trial landscape by route of administration related to the pulmonary embolism market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PULMONARY EMBOLISM - INTRODUCTION

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

5 PULMONARY EMBOLISM - DISEASE OVERVIEW

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

6 PATIENT JOURNEY

7 PULMONARY EMBOLISM - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 PULMONARY EMBOLISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PULMONARY EMBOLISM - UNMET NEEDS

10 PULMONARY EMBOLISM - KEY ENDPOINTS OF TREATMENT

11 PULMONARY EMBOLISM - MARKETED PRODUCTS

- 11.1 List of Pulmonary embolism Marketed Drugs Across the Top 7 Markets

- 11.1.1 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Activase (Alteplase) - Boehringer Ingelheim
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Savaysa (Edoxaban) - Daiichi Sankyo
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Arixtra (Fondaparinux sodium) - Sanofi aventis
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson Pharmaceutical
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PULMONARY EMBOLISM - PIPELINE DRUGS

- 12.1 List of Pulmonary embolism Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Recombinant staphylokinase - Supergene
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 TS23 - Translational Sciences
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 Abelaclimab - Anthos Therapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 DS 1040b - Daiichi Sankyo
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Recombinant Human Prourokinase - Tasly Pharmaceutical
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PULMONARY EMBOLISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PULMONARY EMBOLISM – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PULMONARY EMBOLISM - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Pulmonary Embolism - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Pulmonary Embolism - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Pulmonary Embolism - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Pulmonary Embolism - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Pulmonary Embolism - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Pulmonary Embolism - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Pulmonary Embolism - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Pulmonary Embolism - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Pulmonary Embolism - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Pulmonary Embolism - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Pulmonary Embolism - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Pulmonary Embolism - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Pulmonary Embolism - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Pulmonary Embolism - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Pulmonary Embolism - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Pulmonary Embolism - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Pulmonary Embolism - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Pulmonary Embolism - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Pulmonary Embolism - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Pulmonary Embolism - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Pulmonary Embolism - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Pulmonary Embolism - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Pulmonary Embolism - Access and Reimbursement Overview

16 PULMONARY EMBOLISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PULMONARY EMBOLISM MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PULMONARY EMBOLISM MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Pulmonary Embolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PFC1F1E9CCD7EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFC1F1E9CCD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

